Intervention time modified the effect of inulin on high‐fat diet‐induced obesity and gut microbial disorders

Abstract

Various epidemiological studies support that inulin improves the intestinal environment and decreases the risk of obesity. The same as host feeding rhythms, gut microbiota itself displays daily fluctuations in composition and function. The purpose of this study was to investigate the influences of intervention time of inulin to alleviate high‐fat diet (HFD)‐induced obesity based on chrono‐nutrition. Male C57BL/6J mice were given HFD and gavaged inulin at light‐on time (HFM) or light‐off time (HFN) daily. Energy expenditure (EE), 16S rRNA sequencing in colonic contents, and short‐chain fatty acids (SCFAs) analysis were carried out after 12 weeks. Both in HFM and HFN group, the HFD‐induced weight gain was significantly reduced by 20.91% and 23.32%, and the mice in HFN group showed no significant difference in weight gain with the control group. Besides, mice in HFN group showed a tendency to increase EE and fecal SCFAs contents in addition to the relative content of colonic beneficial bacteria. As the light‐off period of mice is their active period, these results suggested that inulin intake at active period exhibited relatively stronger effects on ameliorating obesity and improving the gut microbial environment.

Exploring the potential mechanism of Rubus corchorifolius L. fruit polyphenol-rich extract in mitigating non-alcoholic fatty liver disease by integration of metabolomics and transcriptomics profiling

“…In the past few decades, there has been a marked rise in NAFLD cases, mirroring the growing obesity epidemic. 2 NAFLD is closely connected with glucose and lipid metabolism disorder, oxidative stress, mitochondrial dysfunction, and inflammation. Nowadays, there has been a growing interest in understanding the effect of phenolic compounds, such as cyanidin derived from red-colored berries, in alleviating HFD-induced NAFLD.…”

“…This, in turn, disrupts the liver's ability to metabolize lipids, leading to increased oxidative stress, inflammation, and even fibrogenesis. 2,3 NAFLD is a complex phenotype that progresses through four stages: nonalcoholic fatty liver, nonalcoholic steatohepatitis, fibrosis, and cirrhosis. 4 Although we now have a better understanding of NAFLD's pathogenesis and therapeutic targets, no approved medications are currently available for its treatment.…”